Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for confidential information.
This move was revealed after a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson later clarified that the United States was requesting genetic material for research and commercial purposes while was not willing to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to secure a deal agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar situation in neighbouring Kenya, where a court halted a similar deal with the US after concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and accountability.
As per statements, Sixteen African countries have so far agreed to these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, without any equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our country would provide the basic resources for medical research with no certainty that the final treatments would be accessible to our people if a new health crisis arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting systems previously established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This system is designed to ensure that when a nation contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We encourage continued discussions with our American counterparts on how future collaboration could be arranged in a manner that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but suggested that talks need to persist considering a large portion of the nation's HIV programmes depended on foreign aid.
"If technical issues arise, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group added.
The situation highlights the ongoing debate between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.